Eli Lilly and Company (LLY)
|
34.33
+0.13 (+0.38%)
|
|
|
|
InvestorGuide Stock Analysis
Eli Lilly Announces Restructuring Plan, 5,500 Job Cuts
Excerpt from the InvestorGuide.com Stock of the Day on 9/14/2009
Most of the time, headlines relating to Eli Lilly revolve around questionable drug trials, newly released medicines, or the occasional acquisition. With many companies, regardless of the product or service the company provides, the product or service is not always the headline issue behind most of the company's news; sometimes, a company simply needs to increase profits or file for bankruptcy. However, even as Eli Lilly announced what appeared to be a straightforward restructuring plan, if you look closer you couldn't help but see that their products were still a prominent feature in this announcement.
As with just about any restructuring plan, for Eli Lilly and Co. there is a financial motivation. The company is hoping to save $1 billion, and its first effort towards doing that is by the removal of 5,500 jobs. The company will be cutting these 5,500 positions (out of their existing 40,500 employees) by 2011. Along with the job cuts, the company also plans to implement a new organizational structure. Once reorganized, the company will have five primary business units, which will include oncology, diabetes, emerging markets, established markets, and animal health. More »
Excerpt from the InvestorGuide.com Stock of the Day on 9/14/2009
Most of the time, headlines relating to Eli Lilly revolve around questionable drug trials, newly released medicines, or the occasional acquisition. With many companies, regardless of the product or service the company provides, the product or service is not always the headline issue behind most of the company's news; sometimes, a company simply needs to increase profits or file for bankruptcy. However, even as Eli Lilly announced what appeared to be a straightforward restructuring plan, if you look closer you couldn't help but see that their products were still a prominent feature in this announcement.
As with just about any restructuring plan, for Eli Lilly and Co. there is a financial motivation. The company is hoping to save $1 billion, and its first effort towards doing that is by the removal of 5,500 jobs. The company will be cutting these 5,500 positions (out of their existing 40,500 employees) by 2011. Along with the job cuts, the company also plans to implement a new organizational structure. Once reorganized, the company will have five primary business units, which will include oncology, diabetes, emerging markets, established markets, and animal health. More »
Trading Offers |
Special Offers |
InvestorGuide Stock of the Day RSS feed RSS
Eli Lilly to Buy ImClone for $6.5 Billion
Excerpt from the InvestorGuide.com Stock of the Day on 10/6/2008
In a market plagued by tight credit and bankruptcies, pharmaceutical giant, Eli Lilly and Company, has agreed to acquire ImClone Systems Inc (IMCL: Charts, News, Offers) for $6.5 billion in a all cash deal that would expand its pipeline of cancer treatments. The deal values ImClone at $70 per share, a premium of 51% to ImClone's closing price on July 30. New York-based ImClone had previously rejected two lower-priced takeover offers from Bristol-Myers Squibb (BMY: Charts, News, Offers). Both ImClone and Eli Lilly's boards have expressed approval of the deal however Bristol-Myers Squibb currently owns a 17% stake in ImClone. Can we expect Bristol, which previously sweetened its offer to $62 a share, to come back with a counter-offer? Or will Eli Lilly be able to seal the deal with the infamous pharmaceutical research company? More »Eli Lilly on the Hot Seat After Stopping Drug Test
Excerpt from the InvestorGuide.com Stock of the Day on 10/26/2007
Eli Lilly is at a fork in the road. The problem is that the company might not have a huge choice when it comes to the direction that it gets to take. The path to the right has the FDA approve Lilly's new blood thinner drug, prasugrel, allowing it to compete with the likes of Bristol-Myers Squibb's (BMY: Charts, News, Offers) Plavik. To the left the company faces an FDA disapproval or a return to more expensive testing, something that will make both doctors and investors edgy. With mounting pressure to create a new blockbuster drug, will the Indianapolis-based pharmaceutical company crack or will it rise to the occasion? More »Eli Lilly Expects to Beat 2006 Forecasts, Enjoys Tax Break
Excerpt from the InvestorGuide.com Stock of the Day on 12/9/2005
Eli Lilly announced Friday that it expects to beat analysts' earnings expectations for 2006, pulling in an estimated $3.10 to $3.20 a share. The news comes as the company moves to market some its pharmaceutical products to cover new illnesses, which can boost the company's growth rate to nearly double what most other large companies in the drug industry are estimated to reach. The Indianapolis, Indiana-based company makes a series of pharmaceutical drugs, including such widely-recognized names as Prozac and Cialis. Considering the recent shortcomings of Merck, what is Eli Lilly doing to hedge itself from its own set of risks? More »Special Offers
LLY analyst ratings
Special Offers
Competitors
Eli Lilly and Company (LLY) Upgrades
Date
Analyst
Old Rating
New Rating
07/13/2009
Natixis Bleichroeder
Hold
Buy
03/18/2009
Citi
Hold
Buy
02/01/2007
Prudential Equity
Overweight
Neutral Weight
Eli Lilly and Company (LLY) Downgrades
Date
Analyst
Old Rating
New Rating
08/04/2010
Jefferies & Co
Buy
Hold PT $ 38
04/20/2010
Hapoalim Securities
Hold
Sell
12/11/2009
Caris & Co.
Above Average
Average
10/09/2008
This morning, Credit Suisse
Outperform
Neutral
09/16/2008
J. P. Morgan
Neutral
Underweight
11/05/2007
HSBC
Neutral
Underweight
Eli Lilly and Company (LLY) New Coverage
Date
Analyst
Rating
10/08/2009
Wells Fargo
Market Perform
07/15/2009
Morgan Stanley
Underweight
07/18/2008
Citi
Neutral
LLY Links
•
Guru Analysis:
•
Analyst Opinions:
•
Blogs:
•
Message Boards:
•
Trading Offers:
Research Assistant
How to use this tool
How to use this tool
